Pancreatic cancer is the fourth most lethal cancer with disappointing prognosis not exceeding 4%for year-5 patients.Around 8,000 patients are diagnosed with pancreatic cancer annually and is the ninth most common cancer in the UK.Gemcitabine is the front line drug for pancreatic cancer,with relatively moderate therapeutic potency due to poor drug pharmacokinetics,high dosage required for effective therapy,and the development of drug resistance.Therefore,the development of new therapeutic modalities for pancreatic cancer is desperately needed.